Ulisse Biomed S.p.A. (BIT:UBM)
Italy flag Italy · Delayed Price · Currency is EUR
0.7600
+0.0100 (1.33%)
Apr 28, 2025, 11:42 AM CET

Ulisse Biomed Statistics

Total Valuation

Ulisse Biomed has a market cap or net worth of EUR 18.36 million. The enterprise value is 17.19 million.

Market Cap 18.36M
Enterprise Value 17.19M

Important Dates

The next estimated earnings date is Friday, June 27, 2025.

Earnings Date Jun 27, 2025
Ex-Dividend Date n/a

Share Statistics

Ulisse Biomed has 24.48 million shares outstanding.

Current Share Class n/a
Shares Outstanding 24.48M
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float n/a

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 23.91
PB Ratio 0.78
P/TBV Ratio 4.35
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -2.89
EV / Sales 22.39
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -4.83

Financial Position

The company has a current ratio of 1.70, with a Debt / Equity ratio of 0.01.

Current Ratio 1.70
Quick Ratio 1.11
Debt / Equity 0.01
Debt / EBITDA n/a
Debt / FCF -0.09
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -23.28% and return on invested capital (ROIC) is -13.92%.

Return on Equity (ROE) -23.28%
Return on Assets (ROA) -12.17%
Return on Invested Capital (ROIC) -13.92%
Return on Capital Employed (ROCE) -23.87%
Revenue Per Employee 95,991
Profits Per Employee -742,477
Employee Count 10
Asset Turnover 0.03
Inventory Turnover 0.74

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -40.94% in the last 52 weeks. The beta is 0.70, so Ulisse Biomed's price volatility has been lower than the market average.

Beta (5Y) 0.70
52-Week Price Change -40.94%
50-Day Moving Average 0.78
200-Day Moving Average 0.89
Relative Strength Index (RSI) 46.66
Average Volume (20 Days) 18,950

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Ulisse Biomed had revenue of EUR 767,929 and -5.94 million in losses.

Revenue 767,929
Gross Profit -622,385
Operating Income -5.77M
Pretax Income -5.94M
Net Income -5.94M
EBITDA -2.85M
EBIT -5.77M
Earnings Per Share (EPS) n/a
Full Income Statement

Balance Sheet

The company has 1.50 million in cash and 333,889 in debt, giving a net cash position of 1.17 million or 0.05 per share.

Cash & Cash Equivalents 1.50M
Total Debt 333,889
Net Cash 1.17M
Net Cash Per Share 0.05
Equity (Book Value) 23.67M
Book Value Per Share n/a
Working Capital 2.14M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.56 million and capital expenditures -2,168, giving a free cash flow of -3.56 million.

Operating Cash Flow -3.56M
Capital Expenditures -2,168
Free Cash Flow -3.56M
FCF Per Share -0.15
Full Cash Flow Statement

Margins

Gross Margin -81.05%
Operating Margin -751.77%
Pretax Margin -773.49%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Ulisse Biomed does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield n/a
Earnings Yield -32.35%
FCF Yield -19.40%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Ulisse Biomed has an Altman Z-Score of 2.81. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.81
Piotroski F-Score n/a